Business Model Breakdown
How Cryo-Cell International Inc Makes Money
CCEL
Market Cap
$37M
Annual Revenue
$32M
Profit Margin
-1.5%
The Short Version
Cryo-Cell International primarily operates as a private cord blood bank, offering long-term storage of umbilical cord blood and tissue stem cells for future therapeutic use by families. This established business provides a recurring revenue stream through storage fees. The company is also attempting a strategic pivot into the broader, higher-growth cell therapy sector through research and development and potential partnerships, aiming to leverage its expertise in stem cell processing and storage for new medical treatments and applications. The success of this pivot is currently hindered by significant financial challenges.
Where the Revenue Comes From
Stem cell storage fees (primary, recurring revenue)
Potential future revenues from cell therapy applications (nascent, currently speculative)
Who buys: Parents and families opting for private stem cell banking services; potentially healthcare institutions, researchers, or pharmaceutical companies for future cell therapy products.
Why It Works (Competitive Advantages)
- ✔Historical first-mover advantage as the world's first private cord blood bank (since 1992)
- ✔Established infrastructure and operational expertise in stem cell processing and storage
Economic Moat: Narrow (Brand Power (historical recognition), Intangible Assets/IP (related to established operational processes and historical data))
What Our Analysis Says
DVR Score as of April 9, 2026
Cryo-Cell International is in severe financial distress, highlighted by the NYSE American noncompliance notice, a reported stockholders' deficit, and persistent net losses across FY2023-2025. The current ratio of 0.59 indicates significant liquidity pressures. While the company has an established core cord blood banking business and a strategic vision for high-growth cell therapy, its current financial state, including delisting risk, fundamentally undermines any near-term 10x growth potential. The focus is on survival and solvency, not exponential expansion. The cell therapy pivot, though appealing, remains unproven and severely constrained by the company's lack of capital and profitability.